The Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) has celebrated its 25th anniversary with some 550 invited guests. At the same time, the Board of Directors honored five individuals to whom the MDC owes a large debt of gratitude, especially during the early years.
A new study in the journal Nature reveals that a small signaling molecule has the ability to cut off the blood supply to tumors. This allows the immune system’s T-cells to indirectly fight cancer.
The causes of preeclampsia are still unknown. A new study has now shown that those affected by the disease have lower quantities of the placenta’s immune protein CD74, and that certain inflammatory factors are higher.
Sometimes the line between what’s good and bad is very thin. One of the topics at this year’s EU-LIFE Scientific Workshop was the fact that the effects of promising therapeutic strategies for cancer can be the opposite of those that are intended.
Rare diseases – sometimes referred to as “orphan diseases” – get left behind in the development of new treatments because of their low prevalence: because patient numbers are small, clinical studies are difficult to conduct and the pharmaceutical industry has no commercial interest in the issue. What can help here is close cooperation between publicly […]